Heart Failure: key endpoint results by drug

The key endpoints of Heart Failure trials, with each approved or late-stage drug's result from its own trial: the lead dose against placebo (or the trial's active comparator), the week, and the arm size. These are the same rows as the drug comparison, for every drug at once. To set chosen drugs side by side, with every shared endpoint, use the comparison. The drug list and pipeline are on the Heart Failure page.

CV death or HF hospitalisation

CV death or HF hospitalisation in Heart Failure: 4 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
Dapagliflozin16.1%20.9%−4.810 mg · n 2373NCT03036124 Phase 3, secondary
Ivabradine24.5%28.7%−4.2n 3241NCT02441218 Phase 3, primary
Omecamtiv mecarbil37%39.1%−2.1n 4120NCT02929329 Phase 3, primary
Sacubitril/valsartan10.9%11.8% (Ramipril)—n 2830NCT02924727 Phase 3, secondary

Drugs checked with no result here: 14 trial running, 14 not reported, 10 not posted.

HF hospitalisation

HF hospitalisation in Heart Failure: 5 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
Empagliflozin5.3%4.5%+0.810 mg · n 265NCT04157751 Phase 3, secondary
Ferric carboxymaltose25.4%32.4%−7wk 52 · n 558NCT02937454 Phase 4, secondary
Ivabradine15.9%20.6%−4.7n 3241NCT02441218 Phase 3, secondary
Omecamtiv mecarbil27.7%28.7%−1n 4120NCT02929329 Phase 3, secondary
Sacubitril/valsartan22.1%24.1% (Enalapril)—n 462NCT04023227 Phase 4, primary

Drugs checked with no result here: 14 trial running, 14 not reported, 9 not posted.

CV death

CV death in Heart Failure: 4 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
Dapagliflozin7.4%8.3%−0.910 mg · n 3131NCT03619213 Phase 3, secondary
Ivabradine13.9%15%−1.1n 3241NCT02441218 Phase 3, secondary
Omecamtiv mecarbil19.6%19.4%+0.2n 4120NCT02929329 Phase 3, secondary
Sacubitril/valsartan23.8%25.4% (Enalapril)—n 462NCT04023227 Phase 4, primary

Drugs checked with no result here: 14 trial running, 14 not reported, 10 not posted.

KCCQ clinical summary, change

KCCQ clinical summary, change in Heart Failure: 4 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
Dapagliflozin68.662.8+5.8wk 12 · n 162NCT03030235 Phase 4, primary
Empagliflozin4.53.2+1.310 mg · wk 52 · n 2333NCT03057951 Phase 3, secondary
Finerenone21.324.3 (Eplerenone)—2.5-5 mg OD · wk 12.86 · n 161NCT01807221 Phase 2, secondary
Sacubitril/valsartan-1.5-2.5 (Valsartan)—wk 32 · n 2407NCT01920711 Phase 3, secondary

Drugs checked with no result here: 14 trial running, 15 not reported, 9 not posted.

  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. Rows are in drug-name order, not ranked. Difference is the lead arm minus placebo, in the endpoint's unit. 42 approved or late-stage drugs with a featured trial in Heart Failure were checked; results come from ClinicalTrials.gov posted results unless marked. Updated 2026-11-20. How results are chosen: methodology.